- Home
- BBIO vs LBRDA Comparison
BBIO vs LBRDA Comparison
Compare BBIO & LBRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- LBRDA
- Stock Information
- Founded
- BBIO 2015
- LBRDA 2014
- Country
- BBIO United States
- LBRDA United States
- Employees
- BBIO N/A
- LBRDA N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- LBRDA Cable & Other Pay Television Services
- Sector
- BBIO Health Care
- LBRDA Telecommunications
- Exchange
- BBIO Nasdaq
- LBRDA Nasdaq
- Market Cap
- BBIO 10.4B
- LBRDA 8.3B
- IPO Year
- BBIO 2019
- LBRDA N/A
- Fundamental
- Price
- BBIO $61.73
- LBRDA $50.21
- Analyst Decision
- BBIO Strong Buy
- LBRDA Buy
- Analyst Count
- BBIO 18
- LBRDA 2
- Target Price
- BBIO $74.28
- LBRDA $105.00
- AVG Volume (30 Days)
- BBIO 2.7M
- LBRDA 97.4K
- Earning Date
- BBIO 10-29-2025
- LBRDA 11-05-2025
- Dividend Yield
- BBIO N/A
- LBRDA N/A
- EPS Growth
- BBIO N/A
- LBRDA 1.38
- EPS
- BBIO N/A
- LBRDA 5.51
- Revenue
- BBIO $353,780,000.00
- LBRDA $1,016,000,000.00
- Revenue This Year
- BBIO $123.32
- LBRDA $8.37
- Revenue Next Year
- BBIO $73.46
- LBRDA $2.91
- P/E Ratio
- BBIO N/A
- LBRDA $9.14
- Revenue Growth
- BBIO 62.46
- LBRDA 306.40
- 52 Week Low
- BBIO $21.72
- LBRDA $49.07
- 52 Week High
- BBIO $69.48
- LBRDA $95.95
- Technical
- Relative Strength Index (RSI)
- BBIO 59.65
- LBRDA 28.28
- Support Level
- BBIO $60.23
- LBRDA $49.53
- Resistance Level
- BBIO $64.44
- LBRDA $52.00
- Average True Range (ATR)
- BBIO 3.05
- LBRDA 1.87
- MACD
- BBIO 0.06
- LBRDA -0.54
- Stochastic Oscillator
- BBIO 53.68
- LBRDA 11.91
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About LBRDA Liberty Broadband Corporation
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.